JP5452490B2 - キナーゼ阻害剤の組成物ならびに癌およびキナーゼに関連する他の疾患の治療のためのそれらの使用 - Google Patents

キナーゼ阻害剤の組成物ならびに癌およびキナーゼに関連する他の疾患の治療のためのそれらの使用 Download PDF

Info

Publication number
JP5452490B2
JP5452490B2 JP2010524187A JP2010524187A JP5452490B2 JP 5452490 B2 JP5452490 B2 JP 5452490B2 JP 2010524187 A JP2010524187 A JP 2010524187A JP 2010524187 A JP2010524187 A JP 2010524187A JP 5452490 B2 JP5452490 B2 JP 5452490B2
Authority
JP
Japan
Prior art keywords
substituted
cancer
alkyl
aryl
heterocycle
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2010524187A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010538091A (ja
JP2010538091A5 (show.php
Inventor
チャン チア リー，
チー−フェン リー，
ユーチー リー，
ウェイ リー，
ハリー ロゴフ，
Original Assignee
ボストン バイオメディカル， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ボストン バイオメディカル， インコーポレイテッド filed Critical ボストン バイオメディカル， インコーポレイテッド
Publication of JP2010538091A publication Critical patent/JP2010538091A/ja
Publication of JP2010538091A5 publication Critical patent/JP2010538091A5/ja
Application granted granted Critical
Publication of JP5452490B2 publication Critical patent/JP5452490B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Vascular Medicine (AREA)
  • Dermatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Emergency Medicine (AREA)
JP2010524187A 2007-09-06 2008-09-05 キナーゼ阻害剤の組成物ならびに癌およびキナーゼに関連する他の疾患の治療のためのそれらの使用 Expired - Fee Related JP5452490B2 (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US97041007P 2007-09-06 2007-09-06
US60/970,410 2007-09-06
US1338907P 2007-12-13 2007-12-13
US61/013,389 2007-12-13
US7429508P 2008-06-20 2008-06-20
US61/074,295 2008-06-20
PCT/US2008/075418 WO2009033033A2 (en) 2007-09-06 2008-09-05 Compositions of kinase inhibitors and their use for treatment of cancer and other diseases related to kinases

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2013272195A Division JP5701372B2 (ja) 2007-09-06 2013-12-27 キナーゼ阻害剤の組成物ならびに癌およびキナーゼに関連する他の疾患の治療のためのそれらの使用

Publications (3)

Publication Number Publication Date
JP2010538091A JP2010538091A (ja) 2010-12-09
JP2010538091A5 JP2010538091A5 (show.php) 2011-10-27
JP5452490B2 true JP5452490B2 (ja) 2014-03-26

Family

ID=40429714

Family Applications (5)

Application Number Title Priority Date Filing Date
JP2010524187A Expired - Fee Related JP5452490B2 (ja) 2007-09-06 2008-09-05 キナーゼ阻害剤の組成物ならびに癌およびキナーゼに関連する他の疾患の治療のためのそれらの使用
JP2013272195A Expired - Fee Related JP5701372B2 (ja) 2007-09-06 2013-12-27 キナーゼ阻害剤の組成物ならびに癌およびキナーゼに関連する他の疾患の治療のためのそれらの使用
JP2015028165A Expired - Fee Related JP5974124B2 (ja) 2007-09-06 2015-02-17 キナーゼ阻害剤の組成物ならびに癌およびキナーゼに関連する他の疾患の治療のためのそれらの使用
JP2016140101A Expired - Fee Related JP6495868B2 (ja) 2007-09-06 2016-07-15 キナーゼ阻害剤の組成物ならびに癌およびキナーゼに関連する他の疾患の治療のためのそれらの使用
JP2019021397A Pending JP2019070051A (ja) 2007-09-06 2019-02-08 キナーゼ阻害剤の組成物ならびに癌およびキナーゼに関連する他の疾患の治療のためのそれらの使用

Family Applications After (4)

Application Number Title Priority Date Filing Date
JP2013272195A Expired - Fee Related JP5701372B2 (ja) 2007-09-06 2013-12-27 キナーゼ阻害剤の組成物ならびに癌およびキナーゼに関連する他の疾患の治療のためのそれらの使用
JP2015028165A Expired - Fee Related JP5974124B2 (ja) 2007-09-06 2015-02-17 キナーゼ阻害剤の組成物ならびに癌およびキナーゼに関連する他の疾患の治療のためのそれらの使用
JP2016140101A Expired - Fee Related JP6495868B2 (ja) 2007-09-06 2016-07-15 キナーゼ阻害剤の組成物ならびに癌およびキナーゼに関連する他の疾患の治療のためのそれらの使用
JP2019021397A Pending JP2019070051A (ja) 2007-09-06 2019-02-08 キナーゼ阻害剤の組成物ならびに癌およびキナーゼに関連する他の疾患の治療のためのそれらの使用

Country Status (15)

Country Link
US (5) US8299106B2 (show.php)
EP (2) EP2197878B1 (show.php)
JP (5) JP5452490B2 (show.php)
CN (1) CN101848908B (show.php)
CA (1) CA2736177A1 (show.php)
CY (1) CY1118012T1 (show.php)
DK (1) DK2197878T3 (show.php)
ES (2) ES2591028T3 (show.php)
HR (1) HRP20161114T1 (show.php)
HU (1) HUE030774T2 (show.php)
LT (1) LT2197878T (show.php)
PL (1) PL2197878T3 (show.php)
PT (1) PT2197878T (show.php)
SI (1) SI2197878T1 (show.php)
WO (1) WO2009033033A2 (show.php)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5452490B2 (ja) * 2007-09-06 2014-03-26 ボストン バイオメディカル， インコーポレイテッド キナーゼ阻害剤の組成物ならびに癌およびキナーゼに関連する他の疾患の治療のためのそれらの使用
JP5754942B2 (ja) * 2007-12-10 2015-07-29 インターデイジタル パテント ホールディングス インコーポレイテッド 無線リンク制御パケットの破棄および無線リンク制御の再確立をトリガする方法および装置
JP2014509323A (ja) 2011-02-28 2014-04-17 マックマスター ユニヴァーシティ ドーパミン受容体遮断薬による癌の処置
US9550764B2 (en) 2012-08-23 2017-01-24 The Institute Of Cancer Research: Royal Cancer Hospital Fused heterocyclic compounds and their use
US9227962B2 (en) 2013-03-13 2016-01-05 Boston Biomedical, Inc. Heterocyclic substituted-3-heteroarylidenyl-2-indolinone derivative
US9187454B2 (en) 2013-03-13 2015-11-17 Boston Biomedical, Inc. Inhibitors of kinases and cancer stem cells, and methods of preparation and use thereof
WO2014160401A1 (en) * 2013-03-13 2014-10-02 Boston Biomedical, Inc. 3-(aryl or heteroaryl) methyleneindolin-2-one derivatives as inhibitors of cancer stem cell pathway kinases for the treatment of cancer
WO2014202528A1 (en) * 2013-06-20 2014-12-24 Boehringer Ingelheim International Gmbh Olefin substituted oxindoles having ampk activity
CN106132412A (zh) * 2014-01-27 2016-11-16 北京强新生物科技有限公司 治疗癌症的新方法
WO2016057931A1 (en) 2014-10-10 2016-04-14 The Research Foundation For The State University Of New York Trifluoromethoxylation of arenes via intramolecular trifluoromethoxy group migration
AU2016255034A1 (en) * 2015-04-27 2017-11-02 Boston Biomedical, Inc. Methods for treating cancer with a STAT3 pathway inhibitor and kinase inhibitor
US10377749B2 (en) 2015-08-10 2019-08-13 Sumitomo Dainippon Pharma Co., Ltd. Purification method for 5-(thiazol-4-yl)indolin-2-one derivative
WO2017160978A1 (en) 2016-03-15 2017-09-21 Boston Biomedical, Inc. Cell cultures and use thereof
JP2019519573A (ja) 2016-06-28 2019-07-11 ボストン バイオメディカル， インコーポレイテッド がんを処置するための方法
WO2018098352A2 (en) 2016-11-22 2018-05-31 Jun Oishi Targeting kras induced immune checkpoint expression
CA3045306A1 (en) 2016-11-29 2018-06-07 Boston Biomedical, Inc. Naphthofuran derivatives, preparation, and methods of use thereof
JP7589949B2 (ja) * 2018-09-18 2024-11-26 １グローブ バイオメディカル カンパニー， リミテッド 肥満に対する処置
US12318381B2 (en) * 2018-09-18 2025-06-03 1Globe Biomedical Co., Ltd. Treatment for non-alcoholic fatty liver disease
CA3237696A1 (en) 2021-11-08 2023-05-11 Progentos Therapeutics, Inc. Platelet-derived growth factor receptor (pdgfr) alpha inhibitors and uses thereof

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2829451B2 (ja) * 1990-11-30 1998-11-25 大塚製薬株式会社 活性酸素抑制剤
EP0929520B1 (en) * 1996-08-23 2005-11-02 Sugen, Inc. Indolinone combinatorial libraries and related products and methods for the treatment of disease
GB9716557D0 (en) * 1997-08-06 1997-10-08 Glaxo Group Ltd Benzylidene-1,3-dihydro-indol-2-one derivatives having anti-cancer activity
WO1999015524A1 (en) * 1997-09-23 1999-04-01 Fujisawa Pharmaceutical Co., Ltd. Thiazole derivatives
ATE369359T1 (de) * 2000-02-15 2007-08-15 Sugen Inc Pyrrol substituierte indolin-2-on protein kinase inhibitoren
US6465507B2 (en) * 2000-02-28 2002-10-15 Sugen, Inc. 3-(pyrolyllactone)-2-indolinone compounds as kinase inhibitors
EP1294688A2 (en) * 2000-06-02 2003-03-26 Sugen, Inc. Indolinone derivatives as protein kinase/phosphatase inhibitors
JP4343534B2 (ja) * 2001-03-02 2009-10-14 ゲーペーツェー バイオテック アクチェンゲゼルシャフト ３ハイブリッド・アッセイ・システム
WO2002081466A1 (en) 2001-04-09 2002-10-17 Sugen, Inc. Prodrugs of 3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives
US20030119839A1 (en) 2001-12-13 2003-06-26 Nan-Horng Lin Protein kinase inhibitors
SE0200979D0 (sv) * 2002-03-28 2002-03-28 Astrazeneca Ab New compounds
US20050032871A1 (en) * 2002-09-03 2005-02-10 Sugen, Inc. Sulfonylated pyrrole-2-indolinone derivatives as kinase inhibitors
JP2007509173A (ja) * 2003-10-24 2007-04-12 シエーリング アクチエンゲゼルシャフト インドリノン誘導体類及び疾病状態、例えば癌の処理へのそれらの使用
BRPI0707312B1 (pt) * 2006-01-27 2022-06-07 Shanghai Hengrui Pharmacetical Co., Ltd Inibidores de pirrolo [3,2-c] piridina-4-ona 2-indolinona proteína cinase, seu uso e seu processo de fabricação, intermediário e seus processos de fabricação, composição farmacêutica e seu uso
BRPI0811978A2 (pt) * 2007-06-01 2014-11-18 Hoffmann La Roche Compostos, processo para a sua manufatura, composições farmacêuticas que os compreendem, método para o tratamento terapêutico e/ou profilático de enfermidades que são moduladas por inibidores de l-cpt1 e uso dos compostos
JP5452490B2 (ja) * 2007-09-06 2014-03-26 ボストン バイオメディカル， インコーポレイテッド キナーゼ阻害剤の組成物ならびに癌およびキナーゼに関連する他の疾患の治療のためのそれらの使用
US9187454B2 (en) * 2013-03-13 2015-11-17 Boston Biomedical, Inc. Inhibitors of kinases and cancer stem cells, and methods of preparation and use thereof

Also Published As

Publication number Publication date
US20150197517A1 (en) 2015-07-16
ES2591028T3 (es) 2016-11-24
JP2016180013A (ja) 2016-10-13
EP2197878B1 (en) 2016-08-17
US20190248781A1 (en) 2019-08-15
DK2197878T3 (en) 2016-11-14
HRP20161114T1 (hr) 2016-11-04
US20100285006A1 (en) 2010-11-11
JP5701372B2 (ja) 2015-04-15
JP2010538091A (ja) 2010-12-09
JP6495868B2 (ja) 2019-04-03
JP2015129152A (ja) 2015-07-16
LT2197878T (lt) 2016-09-26
HUE030774T2 (hu) 2017-05-29
WO2009033033A3 (en) 2009-04-30
EP3037419A1 (en) 2016-06-29
EP2197878A2 (en) 2010-06-23
ES2759347T3 (es) 2020-05-08
HK1226071A1 (en) 2017-09-22
US20180022743A1 (en) 2018-01-25
US20120321622A1 (en) 2012-12-20
JP2019070051A (ja) 2019-05-09
WO2009033033A2 (en) 2009-03-12
CN101848908B (zh) 2014-07-02
CA2736177A1 (en) 2009-03-12
SI2197878T1 (sl) 2016-10-28
JP2014058573A (ja) 2014-04-03
HK1148529A1 (en) 2011-09-09
CN101848908A (zh) 2010-09-29
EP2197878A4 (en) 2012-02-08
JP5974124B2 (ja) 2016-08-23
EP3037419B1 (en) 2019-09-04
PT2197878T (pt) 2016-11-04
CY1118012T1 (el) 2017-05-17
PL2197878T3 (pl) 2017-01-31
US9725444B2 (en) 2017-08-08
US8299106B2 (en) 2012-10-30

Similar Documents

Publication Publication Date Title
JP5452490B2 (ja) キナーゼ阻害剤の組成物ならびに癌およびキナーゼに関連する他の疾患の治療のためのそれらの使用
RU2686323C2 (ru) Новые соединения и композиции для ингибирования fasn
CN102816175B (zh) 一种杂环并吡啶酮类化合物,其中间体、制备方法和用途
CN107922417B (zh) 蝶啶酮衍生物作为egfr抑制剂的应用
CN112661745A (zh) 用作cdk7激酶抑制剂的化合物及其应用
TW201819380A (zh) 作為抗病毒劑之稠合四環吡啶酮化合物
KR20060115346A (ko) Ｎ―치환된 피라졸릴-아미딜-벤즈이미다졸릴 ｃ―ｋｉｔ억제제
JP2011510004A (ja) タンパク質キナーゼ阻害剤及びその使用
CA3157778A1 (en) Substituted isoindolonyl 2,2'-bipyrimidinyl compounds, analogues thereof, and methods using same
JP2024099669A (ja) アデノシン受容体アンタゴニストとしてのピラゾロピリミジン化合物
JP2023551019A (ja) 重水素化２－芳香族ヘテロ環－３－オキソ－２，３－ジヒドロピリダジン－４－カルボキサミド系阻害剤及びその製造方法並びに応用
CN105461709B (zh) 取代脲衍生物及其在药物中的应用
CN113727981B (zh) 激酶抑制剂及其制备、药物组合物和用途
JP7768770B2 (ja) Ｐｄｌ１チェックポイント阻害剤としての複素環式免疫調節剤
HK1226071B (en) Compositions of kinase inhibitors and their use for treatment of cancer and other diseases related to kinases
KR20250097910A (ko) 포스파티딜이노시톨 3-키나제의 신규 억제제
HK1148529B (en) Compositions of kinase inhibitors and their use for treatment of cancer and other diseases related to kinases
WO2021219140A1 (zh) 一种jak2抑制剂及其应用
HK1244787A1 (zh) 作为吲哚胺2，3-二加氧酶和/或色氨酸2，3-二加氧酶抑制剂的新颖的5或8-取代的咪唑并[1，5-a]吡啶

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110905

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20110905

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120807

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130509

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20130808

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20130815

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20130906

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20130913

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20131008

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20131016

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20131111

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20131204

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20131227

R150 Certificate of patent or registration of utility model

Ref document number: 5452490

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees